कृपया अन्य खोज का प्रयास करें
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company’s lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer’s disease (AD), Parkinson’s disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Michael M. B. Hoffman | 74 | 2014 | Independent Chairman of the Board |
Claudine E. Bruck | 68 | 2015 | Independent Director |
Gregory A. Petsko | - | 2017 | Member of Scientific Advisory Board |
Jeffrey L. Cummings | 74 | - | Chief Medical Advisor & Member of Scientific Advisory Board |
Mark K. White | 67 | 2016 | Independent Director |
Sidney Strickland | - | 2017 | Chairman of Scientific Advisory Board |
Reid S. McCarthy | 69 | 2021 | Independent Director |
Maria L. Maccecchini | 73 | 2008 | Founder, CEO, President & Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है